• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
MSB
Click for more information
5.71% $1.49

MESOBLAST LIMITED - Announcements

Market Cap $1.113B  ! watchlist Created with Sketch. Add to my watchlist

Mesoblast Limited is an Australia-based company, which is engaged in developing... Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. It has established commercial partnerships in Europe and China for certain Phase III assets.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
MSB Japanese Law Expediting Cell Therapy Approvals Takes Effect25/11/14
MSB Chronic Low Back Pain Results Presented at NASSPRICE SENSITIVE13/11/14
MSB Appendix 4C - quarterlyPRICE SENSITIVE31/10/14
MSB Release of Shares from Voluntary Escrow29/10/14
MSB Change of Director's Interest Notice29/10/14
MSB Notice of Annual General Meeting/Proxy Form23/10/14
MSB Annual Report to shareholders23/10/14
MSB MSB PARTNER JCR FILES FOR PRODUCT APPROVALPRICE SENSITIVE01/10/14
MSB Appendix 3B26/09/14
MSB Company Secretary Appointment/Resignation29/08/14
MSB MSB 2014 Annual Financial Results Presentation26/08/14
MSB MSB Unveils Path to Bring its Key Products to MarketPRICE SENSITIVE26/08/14
MSB Preliminary Final ReportPRICE SENSITIVE26/08/14
MSB Pharmaceutical Executive Appointed as Mesoblast CFO25/08/14
MSB Change of Director's Interest Notice22/08/14
MSB Appendix 3B22/08/14
MSB MSB & NIH Agree 120 Patient Trial In End-Stage Heart FailurePRICE SENSITIVE07/08/14
MSB Appendix 4C - quarterlyPRICE SENSITIVE31/07/14
MSB Appendix 3B15/07/14
MSB Circulation Publishes Improved Outcomes with Mesoblast CellsPRICE SENSITIVE25/06/14
MSB Appendix 3B24/06/14
MSB Details of Company Address20/06/14
MSB Type 2 Diabetes Results Presented by Study Investigators19/06/14
MSB Mesoblast Receives $5.05m for Stem Cell Pipeline DevelopmentPRICE SENSITIVE16/06/14
MSBResponse to ASX Price QueryPRICE SENSITIVE06/06/14
MSBMSB Accelerates Plans for Commercial Manufacturing OperationPRICE SENSITIVE28/05/14
MSBAppendix 3B02/05/14
MSBAppendix 4C - quarterlyPRICE SENSITIVE30/04/14
MSBAppendix 3B30/04/14
MSBMESOBLAST PROVIDES UPDATE ON CLINICAL PROGRAMS OF PROCHYMALPRICE SENSITIVE29/04/14
MSBResponse to ASX price queryPRICE SENSITIVE08/04/14
MSBKeynote Presentation to Alliance for Regenerative Medicine27/03/14
MSBInitial Director's Interest Notice12/03/14
MSBKey Pharmaceutical Executive Joins Mesoblast11/03/14
MSB2014 Half-Year Financial Results & Corporate Strategy26/02/14
MSBMesoblast Reports Strong Half-Year Financial Results26/02/14
MSBHalf Yearly Report and AccountsPRICE SENSITIVE26/02/14
MSBKey European Patent Granted for Mesoblast's MPCsPRICE SENSITIVE20/02/14
MSBBoardroom Radio Interview with Mesoblast Chief Executive03/02/14
MSBChange in substantial holding03/02/14
MSBAppendix 4C - quarterlyPRICE SENSITIVE31/01/14
MSBPositive Disc Repair Results Using Mesoblast Stem CellsPRICE SENSITIVE30/01/14
MSBBecoming a substantial holder09/01/14
MSBAppendix 3B20/12/13
MSBMesoblast Reports Positive Type 2 Diabetes Trial ResultsPRICE SENSITIVE04/12/13
MSBNew Japanese Regenerative Medicine LegislationPRICE SENSITIVE25/11/13
MSBScrip Award to Mesoblast for 2013 Financing Deal of the Year22/11/13
MSBMPCs Strengthen Cardiac Function in End-Stage Heart FailurePRICE SENSITIVE19/11/13
MSBResults of Meeting15/11/13
MSBCEO Presentation to Shareholders at AGM 201315/11/13
MSBChairman's Address to Shareholders and Remuneration Strategy15/11/13
MSBImproved Survival in Children with GvHD After Cell TherapyPRICE SENSITIVE14/11/13
MSBMPCs Induce Functional Recovery in Ischemic Stroke ModelPRICE SENSITIVE11/11/13
MSBFDA Clears Phase 3 Heart Failure TrialPRICE SENSITIVE31/10/13
MSBMSBs Registration Plans for GVHD Cell Product in JapanPRICE SENSITIVE28/10/13
MSBAppendix 4C - quarterlyPRICE SENSITIVE25/10/13
MSBMesoblast, Intrexon and Ziopharm to Target CancersPRICE SENSITIVE24/10/13
MSBNotice of Annual General Meeting/Proxy Form15/10/13
MSBAnnual Report to shareholders11/10/13
MSBInvestor Update11/10/13
MSBMesoblast Acquires Osiris' Cultured Stem Cell BusinessPRICE SENSITIVE11/10/13
MSBSpinal Fusion Trial to be Presented at Premier Spine Forum19/09/13
MSBAppendix 3B16/09/13
MSBChange of Director's Interest Notice05/09/13
MSBShare Trading Policy02/09/13
MSBStrong Cash Position Enables Execution of Late-Stage Trials29/08/13
MSB2013 Financial Year Results Presentation29/08/13
MSBPreliminary Final ReportPRICE SENSITIVE29/08/13
MSBAppendix 4C - quarterlyPRICE SENSITIVE01/08/13
MSBMSB Receives $4.3M Pipeline Funds from Australian GovernmentPRICE SENSITIVE18/07/13
MSBMSB to Begin Phase 2 Trial of MPCs in Diabetic NephropathyPRICE SENSITIVE26/06/13
MSBKey Mesenchymal Precursor Cell Patent Granted in JapanPRICE SENSITIVE05/06/13
MSBCirculation Research Publishes AMI Preclinical Trial ResultsPRICE SENSITIVE15/05/13
MSBChange in substantial holding14/05/13
MSBAppendix 4C - quarterlyPRICE SENSITIVE30/04/13
MSBAppendix 3B30/04/13
MSBPOSITIVE INTERIM RESULTS IN PHASE 2 TRIAL FOR DISC REPAIRPRICE SENSITIVE22/04/13
MSBInitial Director's Interest Notice22/04/13
MSBDirector Appointment/Resignation17/04/13
MSBCEO AWARDED INAUGURAL PONTIFICAL AWARD FOR INNOVATION12/04/13
MSBChange in substantial holding15/03/13
MSBMESOBLAST COMPLETES A$170M PRIVATE PLACEMENT14/03/13
MSBCleansing Notice Under Section 708A of the Corporations Act14/03/13
MSBAppendix 3B14/03/13
MSBMesoblast Enters into Agreements to Raise A$170millionPRICE SENSITIVE06/03/13
MSBTrading HaltPRICE SENSITIVE04/03/13
MSBFDA Agree on Use of MSBs Singapore Manufacturing Facility13/02/13
MSB2013 1H Results: Strategic Update11/02/13
MSBHalf-Year Results & Strategic Update on Product DevelopmentPRICE SENSITIVE11/02/13
MSBHalf Yearly Report and AccountsPRICE SENSITIVE11/02/13
MSBKEY MPC PATENTS GRANTED IN UNITED STATES AND CHINAPRICE SENSITIVE07/02/13
MSBAppendix 4C - quarterlyPRICE SENSITIVE31/01/13
MSBAppendix 3B31/01/13
MSBFDA CLEARS PHASE 2 CLINICAL TRIAL FOR RHEUMATOID ARTHRITISPRICE SENSITIVE30/01/13
MSBMSB Presents at JP Morgan US Healthcare Conference 201311/01/13
MSBPositive Results in Phase 2 Lumbar Spinal Fusion TrialPRICE SENSITIVE11/01/13
MSBBlood Cell Expansion Trial - New England Journal Of Medicine13/12/12
MSBResults of Meeting29/11/12
MSBMesoblast Corporate Overview - CEO Message to AGMPRICE SENSITIVE29/11/12
MSBChairman's speech and CEO presentation to 2012 AGM29/11/12
MSB Japanese Law Expediting Cell Therapy Approvals Takes Effect
25/11/14
MSB Chronic Low Back Pain Results Presented at NASS
13/11/14PRICE SENSITIVE
MSB Appendix 4C - quarterly
31/10/14PRICE SENSITIVE
MSB Release of Shares from Voluntary Escrow
29/10/14
MSB Change of Director's Interest Notice
29/10/14
MSB Notice of Annual General Meeting/Proxy Form
23/10/14
MSB Annual Report to shareholders
23/10/14
MSB MSB PARTNER JCR FILES FOR PRODUCT APPROVAL
01/10/14PRICE SENSITIVE
MSB Appendix 3B
26/09/14
MSB Company Secretary Appointment/Resignation
29/08/14
MSB MSB 2014 Annual Financial Results Presentation
26/08/14
MSB MSB Unveils Path to Bring its Key Products to Market
26/08/14PRICE SENSITIVE
MSB Preliminary Final Report
26/08/14PRICE SENSITIVE
MSB Pharmaceutical Executive Appointed as Mesoblast CFO
25/08/14
MSB Change of Director's Interest Notice
22/08/14
MSB Appendix 3B
22/08/14
MSB MSB & NIH Agree 120 Patient Trial In End-Stage Heart Failure
07/08/14PRICE SENSITIVE
MSB Appendix 4C - quarterly
31/07/14PRICE SENSITIVE
MSB Appendix 3B
15/07/14
MSB Circulation Publishes Improved Outcomes with Mesoblast Cells
25/06/14PRICE SENSITIVE
MSB Appendix 3B
24/06/14
MSB Details of Company Address
20/06/14
MSB Type 2 Diabetes Results Presented by Study Investigators
19/06/14
MSB Mesoblast Receives $5.05m for Stem Cell Pipeline Development
16/06/14PRICE SENSITIVE
MSBResponse to ASX Price Query
06/06/14PRICE SENSITIVE
MSBMSB Accelerates Plans for Commercial Manufacturing Operation
28/05/14PRICE SENSITIVE
MSBAppendix 3B
02/05/14
MSBAppendix 4C - quarterly
30/04/14PRICE SENSITIVE
MSBAppendix 3B
30/04/14
MSBMESOBLAST PROVIDES UPDATE ON CLINICAL PROGRAMS OF PROCHYMAL
29/04/14PRICE SENSITIVE
MSBResponse to ASX price query
08/04/14PRICE SENSITIVE
MSBKeynote Presentation to Alliance for Regenerative Medicine
27/03/14
MSBInitial Director's Interest Notice
12/03/14
MSBKey Pharmaceutical Executive Joins Mesoblast
11/03/14
MSB2014 Half-Year Financial Results & Corporate Strategy
26/02/14
MSBMesoblast Reports Strong Half-Year Financial Results
26/02/14
MSBHalf Yearly Report and Accounts
26/02/14PRICE SENSITIVE
MSBKey European Patent Granted for Mesoblast's MPCs
20/02/14PRICE SENSITIVE
MSBBoardroom Radio Interview with Mesoblast Chief Executive
03/02/14
MSBChange in substantial holding
03/02/14
MSBAppendix 4C - quarterly
31/01/14PRICE SENSITIVE
MSBPositive Disc Repair Results Using Mesoblast Stem Cells
30/01/14PRICE SENSITIVE
MSBBecoming a substantial holder
09/01/14
MSBAppendix 3B
20/12/13
MSBMesoblast Reports Positive Type 2 Diabetes Trial Results
04/12/13PRICE SENSITIVE
MSBNew Japanese Regenerative Medicine Legislation
25/11/13PRICE SENSITIVE
MSBScrip Award to Mesoblast for 2013 Financing Deal of the Year
22/11/13
MSBMPCs Strengthen Cardiac Function in End-Stage Heart Failure
19/11/13PRICE SENSITIVE
MSBResults of Meeting
15/11/13
MSBCEO Presentation to Shareholders at AGM 2013
15/11/13
MSBChairman's Address to Shareholders and Remuneration Strategy
15/11/13
MSBImproved Survival in Children with GvHD After Cell Therapy
14/11/13PRICE SENSITIVE
MSBMPCs Induce Functional Recovery in Ischemic Stroke Model
11/11/13PRICE SENSITIVE
MSBFDA Clears Phase 3 Heart Failure Trial
31/10/13PRICE SENSITIVE
MSBMSBs Registration Plans for GVHD Cell Product in Japan
28/10/13PRICE SENSITIVE
MSBAppendix 4C - quarterly
25/10/13PRICE SENSITIVE
MSBMesoblast, Intrexon and Ziopharm to Target Cancers
24/10/13PRICE SENSITIVE
MSBNotice of Annual General Meeting/Proxy Form
15/10/13
MSBAnnual Report to shareholders
11/10/13
MSBInvestor Update
11/10/13
MSBMesoblast Acquires Osiris' Cultured Stem Cell Business
11/10/13PRICE SENSITIVE
MSBSpinal Fusion Trial to be Presented at Premier Spine Forum
19/09/13
MSBAppendix 3B
16/09/13
MSBChange of Director's Interest Notice
05/09/13
MSBShare Trading Policy
02/09/13
MSBStrong Cash Position Enables Execution of Late-Stage Trials
29/08/13
MSB2013 Financial Year Results Presentation
29/08/13
MSBPreliminary Final Report
29/08/13PRICE SENSITIVE
MSBAppendix 4C - quarterly
01/08/13PRICE SENSITIVE
MSBMSB Receives $4.3M Pipeline Funds from Australian Government
18/07/13PRICE SENSITIVE
MSBMSB to Begin Phase 2 Trial of MPCs in Diabetic Nephropathy
26/06/13PRICE SENSITIVE
MSBKey Mesenchymal Precursor Cell Patent Granted in Japan
05/06/13PRICE SENSITIVE
MSBCirculation Research Publishes AMI Preclinical Trial Results
15/05/13PRICE SENSITIVE
MSBChange in substantial holding
14/05/13
MSBAppendix 4C - quarterly
30/04/13PRICE SENSITIVE
MSBAppendix 3B
30/04/13
MSBPOSITIVE INTERIM RESULTS IN PHASE 2 TRIAL FOR DISC REPAIR
22/04/13PRICE SENSITIVE
MSBInitial Director's Interest Notice
22/04/13
MSBDirector Appointment/Resignation
17/04/13
MSBCEO AWARDED INAUGURAL PONTIFICAL AWARD FOR INNOVATION
12/04/13
MSBChange in substantial holding
15/03/13
MSBMESOBLAST COMPLETES A$170M PRIVATE PLACEMENT
14/03/13
MSBCleansing Notice Under Section 708A of the Corporations Act
14/03/13
MSBAppendix 3B
14/03/13
MSBMesoblast Enters into Agreements to Raise A$170million
06/03/13PRICE SENSITIVE
MSBTrading Halt
04/03/13PRICE SENSITIVE
MSBFDA Agree on Use of MSBs Singapore Manufacturing Facility
13/02/13
MSB2013 1H Results: Strategic Update
11/02/13
MSBHalf-Year Results & Strategic Update on Product Development
11/02/13PRICE SENSITIVE
MSBHalf Yearly Report and Accounts
11/02/13PRICE SENSITIVE
MSBKEY MPC PATENTS GRANTED IN UNITED STATES AND CHINA
07/02/13PRICE SENSITIVE
MSBAppendix 4C - quarterly
31/01/13PRICE SENSITIVE
MSBAppendix 3B
31/01/13
MSBFDA CLEARS PHASE 2 CLINICAL TRIAL FOR RHEUMATOID ARTHRITIS
30/01/13PRICE SENSITIVE
MSBMSB Presents at JP Morgan US Healthcare Conference 2013
11/01/13
MSBPositive Results in Phase 2 Lumbar Spinal Fusion Trial
11/01/13PRICE SENSITIVE
MSBBlood Cell Expansion Trial - New England Journal Of Medicine
13/12/12
MSBResults of Meeting
29/11/12
MSBMesoblast Corporate Overview - CEO Message to AGM
29/11/12PRICE SENSITIVE
MSBChairman's speech and CEO presentation to 2012 AGM
29/11/12
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
$1.49 		Change
-0.090(5.71%) 		Mkt cap ! $1.113B
Open High Low Value Volume
$1.58 $1.59 $1.47 $7.056M 4.697M

Buyers (Bids)

No. Vol. Price($)
2 3999 $1.48
 

Sellers (Offers)

Price($) Vol. No.
$1.49 46134 7
View Market Depth
Last trade - 16.10pm 21/11/2024 (20 minute delay) ?
Last
$1.48 		  Change
-0.090 ( 5.55 %)
Open High Low Volume
$1.57 $1.57 $1.47 1111085
Last updated 15.59pm 21/11/2024 ?
MSB (ASX) Chart

Top Stories

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
Alcidion inks deal with Vic health provider Peninsula for use of Miya Precision tech Alcidion Group Ltd has signed a contract worth $3.7M to enable use of its Miya Precision platform by users of Peninsula Health entities
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider Wall Street volumes.
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.